French network for inherited hemorragic diseases Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2018
NCT03638817
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

French network for inherited hemorragic diseases

Active Ingredients

Drugs in Phase 2 Trials (1)

eltrombopag (promacta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Thrombocytopenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1